{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:26Z","timestamp":1792813226191,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00751-4","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T03:20:07Z","timestamp":1746242407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Emerging Therapeutic Approaches for Anemia in Myelofibrosis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4960","authenticated-orcid":false,"given":"Helen T.","family":"Chifotides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-4755","authenticated-orcid":false,"given":"Andrea","family":"Duminuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-2969","authenticated-orcid":false,"given":"Elena","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-5157","authenticated-orcid":false,"given":"Calogero","family":"Vetro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-466X","authenticated-orcid":false,"given":"Patrick","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1859-6319","authenticated-orcid":false,"given":"Giuseppe A.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"751_CR1","doi-asserted-by":"publisher","first-page":"103862","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Harrison CN, Mesa R, et al. Anemia in myelofibrosis. Current and emerging treatment options. Cri Rev Oncol Hematol. 2022;180:103862.","journal-title":"Cri Rev Oncol Hematol"},{"issue":"12","key":"751_CR2","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","volume":"101","author":"V Gupta","year":"2016","unstructured":"Gupta V, Harrison C, Hexner EO, et al. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica. 2016;101(12):e482\u20134.","journal-title":"Haematologica"},{"key":"751_CR3","doi-asserted-by":"crossref","unstructured":"Coltoff A, Mascarenhas J. Fedratinib in 2025 and beyond: indications and future applications. Blood Adv. 2025;9(8):1907\u20131915.","DOI":"10.1182\/bloodadvances.2024015365"},{"key":"751_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","volume":"102","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S. How I manage anemia related to myelofibrosis and its treatment regimens. Ann Hematol. 2023;102:689\u201398.","journal-title":"Ann Hematol"},{"issue":"16","key":"751_CR5","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954\u201370.","journal-title":"Blood"},{"issue":"6","key":"751_CR6","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/jcm12062188","volume":"12","author":"A Duminuco","year":"2023","unstructured":"Duminuco A, Nardo A, Giuffrida G, et al. Myelofibrosis and survival prognostic models: a journey between past and future. J Clin Med. 2023;12(6):2188.","journal-title":"J Clin Med"},{"key":"751_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","volume":"13","author":"P Bose","year":"2018","unstructured":"Bose P, Verstovsek S. Management of myelofibrosis-related cytopenias. Curr Hematol Malig Rep. 2018;13:164\u201372.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"751_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"751_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood.2024025459","volume":"145","author":"H Pasquer","year":"2025","unstructured":"Pasquer H, Kiladjian JJ, Benajiba L. Current myeloproliferative neoplasm scoring systems for clinical practice. Blood. 2025;145(3):257\u201376.","journal-title":"Blood"},{"key":"751_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","volume":"366","author":"S Pasca","year":"2022","unstructured":"Pasca S, Chifotides HT, Verstovsek S, Bose P. Mutational landscape of blast phase myeloproliferative neoplasms (BP-MPN) and antecedent MPN. Int Rev Cell Mol Biol. 2022;366:83\u2013124.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"751_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61\u201370.","journal-title":"Blood"},{"issue":"8","key":"751_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/cncr.35156","volume":"130","author":"F Palandri","year":"2024","unstructured":"Palandri F, Palumbo G, Benevolo G, et al. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy. Cancer. 2024;130(8):1270\u201380.","journal-title":"Cancer"},{"issue":"3","key":"751_CR13","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/jha2.745","volume":"4","author":"B Mora","year":"2023","unstructured":"Mora B, Maffioli M, Rumi E, et al. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023;4(3):679\u201389.","journal-title":"EJHaem"},{"issue":"5","key":"751_CR14","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","volume":"32","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Lasho TL, et al. Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia. 2018;32(5):1254\u20138.","journal-title":"Leukemia"},{"issue":"17","key":"751_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood.2024025802","volume":"144","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Barosi G, Passamonti F, et al. Proposals for revised international working group\u2013European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024;144(17):1813\u201320.","journal-title":"Blood"},{"issue":"13","key":"751_CR16","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/cancers15133331","volume":"15","author":"HT Chifotides","year":"2023","unstructured":"Chifotides HT, Verstovsek S, Bose P. Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments. Cancers. 2023;15(13):3331.","journal-title":"Cancers"},{"issue":"8","key":"751_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14656566.2023.2203318","volume":"24","author":"P Vachhani","year":"2023","unstructured":"Vachhani P, Verstovsek S, Prithviraj B. Cytopenic myelofibrosis: prevalence, relevance, and treatment. Expert Opin Pharmacother. 2023;24(8):901\u20138.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"751_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","volume":"37","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Gleitz HFE, Chifotides HT, et al. Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 2022;37(2):255\u201366.","journal-title":"Leukemia"},{"issue":"8","key":"751_CR19","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/cncr.34103","volume":"128","author":"L Masarova","year":"2022","unstructured":"Masarova L, Bose P, Pemmaraju N, et al. Improved survival of patients with myelofibrosis in the last decade: single-center experience. Cancer. 2022;128(8):1658\u201365.","journal-title":"Cancer"},{"issue":"1","key":"751_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","volume":"101","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Parasuraman S, Yu J, et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022;101(1):131\u20137.","journal-title":"Ann Hematol"},{"issue":"2","key":"751_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","volume":"6","author":"P Guglielmelli","year":"2022","unstructured":"Guglielmelli P, Ghirardi A, Carobbio A, et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2022;6(2):373\u20135.","journal-title":"Blood Adv"},{"key":"751_CR23","doi-asserted-by":"crossref","unstructured":"Al-Ali HK, Gerds AT, Grunwald MR, Yu J. A review of real-world experience with ruxolitinib for myelofibrosis. Clin Lymphoma Myeloma Leuk. 2025;25(5):e262-e281.","DOI":"10.1016\/j.clml.2024.12.013"},{"issue":"6","key":"751_CR24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/10428194.2023.2196593","volume":"64","author":"N Pemmaraju","year":"2023","unstructured":"Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma. 2023;64(6):1063\u201381.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"751_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s11899-023-00702-x","volume":"18","author":"A Duminuco","year":"2023","unstructured":"Duminuco A, Torre E, Palumbo GA, et al. A journey through JAK inhibitors for the treatment of myeloproliferative diseases. Curr Hematol Malig Rep. 2023;18(5):176\u201389.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"751_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/bjh.19812","volume":"206","author":"M Breccia","year":"2025","unstructured":"Breccia M, Celant S, Palandri F, et al. The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: a prospective real-world study on AIFA monitoring registries. Br J Haematol. 2025;206(1):172\u20139.","journal-title":"Br J Haematol"},{"issue":"45","key":"751_CR27","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8(45):79073\u201386.","journal-title":"Oncotarget"},{"issue":"6","key":"751_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6(6):1855\u201364.","journal-title":"Blood Adv"},{"issue":"24","key":"751_CR29","doi-asserted-by":"publisher","first-page":"7418","DOI":"10.3390\/jcm11247418","volume":"11","author":"A Duminuco","year":"2022","unstructured":"Duminuco A, Nardo A, Garibaldi B, et al. Prediction of survival and prognosis migration from gold-standard scores in myelofibrosis patients treated with ruxolitinib applying the RR6 prognostic model in a monocentric real-life setting. J Clin Med. 2022;11(24):7418.","journal-title":"J Clin Med"},{"key":"751_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11899-024-00729-8","volume":"19","author":"P Bose","year":"2024","unstructured":"Bose P. Management of patients with early myelofibrosis: a discussion of best practices. Current Hematologic Maligancy Reports. 2024;19:111\u20139.","journal-title":"Current Hematologic Maligancy Reports"},{"issue":"1","key":"751_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001","volume":"1","author":"L Naymagon","year":"2017","unstructured":"Naymagon L, Mascarenhas J. Myelofibrosis-related anemia: current and emerging therapeutic strategies. Hemasphere. 2017;1(1): e1.","journal-title":"Hemasphere"},{"issue":"9","key":"751_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, Le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065\u201373.","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"751_CR33","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1182\/blood-2024-203924","volume":"144","author":"P Vachhani","year":"2024","unstructured":"Vachhani P, Repp J, Hamer-Maanson JE, et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. Blood. 2024;144(Suppl. 1):4546.","journal-title":"Blood"},{"issue":"12","key":"751_CR34","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","volume":"20","author":"F Castillo-Tokumori","year":"2020","unstructured":"Castillo-Tokumori F, Talati C, Al Ali N, et al. Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020;20(12):e956\u201360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl. 1","key":"751_CR35","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1182\/blood-2022-162657","volume":"140","author":"AT Gerds","year":"2022","unstructured":"Gerds AT, Harrison C, Thompson S, et al. The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States. Blood. 2022;140(Suppl. 1):3974\u20135.","journal-title":"Blood"},{"issue":"12","key":"751_CR36","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.18553\/jmcp.2024.24050","volume":"30","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Tkacz J, Moore-Schiltz L, et al. Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: a retrospective analysis of the Medicare Fee-For-Service claims data. J Managed Care Specialty Pharm. 2024;30(12):1395\u2013404.","journal-title":"J Managed Care Specialty Pharm"},{"issue":"4","key":"751_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2023022502","volume":"145","author":"TD Coates","year":"2025","unstructured":"Coates TD. Management of iron overload: lessons from transfusion-dependent hemoglobinopathies. Blood. 2025;145(4):359\u201371.","journal-title":"Blood"},{"key":"751_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1423-0410.2009.01207.x","volume":"97","author":"A Shander","year":"2009","unstructured":"Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang. 2009;97:185\u201397.","journal-title":"Vox Sang"},{"issue":"5","key":"751_CR39","first-page":"e123","volume":"186","author":"EM Elli","year":"2029","unstructured":"Elli EM, Iurlo A, Aroldi A, et al. Deferasirox in the manageent of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study). Br J Haematol. 2029;186(5):e123\u20136.","journal-title":"Br J Haematol"},{"issue":"5","key":"751_CR40","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s12185-020-02861-6","volume":"111","author":"G Caocci","year":"2020","unstructured":"Caocci G, Simula MP, Ghiani S, et al. Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting. Int J Haematol. 2020;111(5):614\u20138.","journal-title":"Int J Haematol"},{"key":"751_CR41","doi-asserted-by":"crossref","unstructured":"Masarova L, Chifotides HT. How I individualize selection of JAK inhibitors for myelofibrosis patients. Blood. 2025;145(16):1724\u20131747.","DOI":"10.1182\/blood.2023022415"},{"issue":"10","key":"751_CR42","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/14656566.2024.2385729","volume":"25","author":"AM Hunter","year":"2024","unstructured":"Hunter AM, Bose P. Advances with Janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024;25(10):1391\u2013404.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"751_CR43","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","volume":"4","author":"P Bose","year":"2020","unstructured":"Bose P, Verstovsek S. JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives. Hemasphere. 2020;4(4):e424.","journal-title":"Hemasphere"},{"issue":"8","key":"751_CR44","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1111\/cts.70018","volume":"17","author":"G Vlasakakis","year":"2024","unstructured":"Vlasakakis G, McCabe MT, Ho YL, et al. Momelotinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(8):e70018.","journal-title":"Clin Transl Sci"},{"issue":"7","key":"751_CR45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2023023719","volume":"144","author":"P Bose","year":"2024","unstructured":"Bose P. Momelotinib for the treatment of myelofibrosis. Blood. 2024;144(7):708\u201313.","journal-title":"Blood"},{"issue":"1","key":"751_CR46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers16010154","volume":"16","author":"A Duminuco","year":"2024","unstructured":"Duminuco A, Chifotides HT, Giallongo S, et al. ACVR1: a novel therapeutic target to treat anemia in myelofibrosis. Cancers. 2024;16(1):154.","journal-title":"Cancers"},{"issue":"6","key":"751_CR48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood.2024024795","volume":"145","author":"AL Fisher","year":"2025","unstructured":"Fisher AL, Phillips S, Wang C-Y, et al. The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice. Blood. 2025;145(6):625\u201334.","journal-title":"Blood"},{"issue":"34","key":"751_CR49","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus Kinase inhibitor na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350.","journal-title":"J Clin Oncol"},{"issue":"7","key":"751_CR50","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/10428194.2024.2328800","volume":"65","author":"V Gupta","year":"2024","unstructured":"Gupta V, Oh S, Devos T, et al. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma. 2024;65(7):965\u201377.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"751_CR51","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1080\/10428194.2022.2043304","volume":"63","author":"R Mesa","year":"2022","unstructured":"Mesa R, Oh ST, Gerds AT, et al. Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leuk Lymphoma. 2022;63(7):1718\u201322.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"751_CR52","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","volume":"36","author":"R Mesa","year":"2022","unstructured":"Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022;36(9):2261\u20138.","journal-title":"Leukemia"},{"issue":"11","key":"751_CR53","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1200\/JCO.21.02246","volume":"40","author":"P Vachhani","year":"2022","unstructured":"Vachhani P, Verstovsek S, Bose P. Disease modification in myelofibrosis. An elusive goal? J Clin Oncol. 2022;40(11):1147\u201354.","journal-title":"J Clin Oncol"},{"issue":"16","key":"751_CR54","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood.2024024220","volume":"144","author":"DM Ross","year":"2024","unstructured":"Ross DM, Lane SW, Harrison CN. Identifying disease-modifying potential in myelofibrosis clinical trials. Blood. 2024;144(16):1679\u201388.","journal-title":"Blood"},{"issue":"13","key":"751_CR55","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.34205","volume":"128","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Verstovsek S, Mesa R, et al. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022;128(13):2420\u201332.","journal-title":"Cancer"},{"issue":"2","key":"751_CR56","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73\u201381.","journal-title":"Lancet Haematol"},{"issue":"9","key":"751_CR57","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s12325-024-02928-4","volume":"41","author":"CN Harrison","year":"2024","unstructured":"Harrison CN, Vannucchi AM, Recher C, et al. Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: subgroup analysis of SIMPLIFY-2. Adv Ther. 2024;41(9):3722\u201335.","journal-title":"Adv Ther"},{"issue":"10373","key":"751_CR58","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401(10373):269\u201380.","journal-title":"Lancet"},{"issue":"9","key":"751_CR59","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","volume":"10","author":"AT Gerds","year":"2023","unstructured":"Gerds AT, Verstovsek S, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023;10(9):e735\u201346.","journal-title":"Lancet Haematol"},{"issue":"11","key":"751_CR60","doi-asserted-by":"publisher","first-page":"e963","DOI":"10.1097\/HS9.0000000000000963","volume":"7","author":"JJ Kiladjian","year":"2023","unstructured":"Kiladjian JJ, Vannucchi AM, Gerds AT, et al. Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials. Hemasphere. 2023;7(11):e963.","journal-title":"Hemasphere"},{"issue":"3","key":"751_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clml.2024.10.001","volume":"25","author":"C Harrison","year":"2025","unstructured":"Harrison C, Mesa R, Talpaz M, et al. Longitudinal assessment of transfusion intensity in patients with JAK inhibitor\u2013naive or \u2013experienced myelofibrosis treated with momelotinib. Clin Lymphoma Myeloma Leuk. 2025;25(3):199\u2013211.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"751_CR62","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","volume":"7","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Mesa R, Gupta V, et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023;7(14):3582\u201391.","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"751_CR63","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1182\/blood-2024-207251","volume":"144","author":"A Rampotas","year":"2024","unstructured":"Rampotas A, Torre E, Brzezinski LC, et al. Real-world efficacy and safety of momelotinib for myelofibrosis: evaluation of a UK-wide study confirms 40% anaemia response rate in a non-clinical trial cohort. Blood. 2024;144(Suppl. 1):1804.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"751_CR64","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood-2024-200698","volume":"144","author":"L P\u00e9rez-Lamas","year":"2024","unstructured":"P\u00e9rez-Lamas L, Diaz AS, Delgado RG, et al. Real-world outcomes of momelotinib as an alternative therapy to other JAK inhibitors in myelofibrosis patients with anemia. Blood. 2024;144(Suppl. 1):1790.","journal-title":"Blood"},{"issue":"16","key":"751_CR65","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","volume":"6","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Mascarenhas J. The Odyssey of pacritinib in myelofibrosis. Blood Adv. 2022;6(16):4905\u201313.","journal-title":"Blood Adv"},{"issue":"19","key":"751_CR66","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","volume":"7","author":"ST Oh","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefits in patients with myelofibrosis. Blood Adv. 2023;7(19):5835\u201342.","journal-title":"Blood Adv"},{"issue":"5","key":"751_CR67","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225\u201336.","journal-title":"Lancet Haematol"},{"issue":"5","key":"751_CR68","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4(5):652\u20139.","journal-title":"JAMA Oncol"},{"issue":"12","key":"751_CR69","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/ajh.26709","volume":"97","author":"Y Hang","year":"2022","unstructured":"Hang Y, Zhou H, Jiang Z, et al. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-na\u00efve patients with myelofibrosis: results of a phase II trial. Am J Hematol. 2022;97(12):1510\u20139.","journal-title":"Am J Hematol"},{"issue":"10","key":"751_CR70","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/ajh.27033","volume":"98","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou H, Duan M, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: a single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023;98(10):1588\u201397.","journal-title":"Am J Hematol"},{"issue":"S3","key":"751_CR71","doi-asserted-by":"publisher","first-page":"e7077553","DOI":"10.1097\/01.HS9.0000967760.70775.53","volume":"7","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhou H, Jungling Z, et al. S212: a randomized double-blind phase 3 study of jaktinib versus hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis. Hemasphere. 2023;7(S3):e7077553.","journal-title":"Hemasphere"},{"issue":"9","key":"751_CR72","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/ajh.27408","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Tefferi A. Targeting anemia in myeloid neoplasms. Am J Hematol. 2024;99(9):1663\u20136.","journal-title":"Am J Hematol"},{"key":"751_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27638","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Gangat N. Therapeutic targeting of the activin receptor signaling pathway: proof of concept in myeloid maligancies. Am J Hematol. 2025;100(5):755\u20137.","journal-title":"Am J Hematol"},{"issue":"8","key":"751_CR74","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","volume":"133","author":"P Fenaux","year":"2019","unstructured":"Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133(8):790\u20134.","journal-title":"Blood"},{"issue":"4","key":"751_CR75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3390\/diseases10040085","volume":"10","author":"E Hatzimichael","year":"2022","unstructured":"Hatzimichael E, Timotheatou D, Koumpis E, et al. Luspatercept: a new tool for the treatment of anemia related to b-thalassemia, myelodysplastic syndromes and primary myelofibrosis. Diseases. 2022;10(4):85.","journal-title":"Diseases"},{"issue":"9","key":"751_CR76","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1016\/S2352-3026(24)00203-5","volume":"11","author":"MG Della Porta","year":"2024","unstructured":"Della Porta MG, Garcia-Manero G, Santini V, et al. Luspatercept versus epoetin alfa in erythropoiesis-stimulating na\u00efve, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomized, controlled trial. Lancet Haematol. 2024;11(9):e646\u201358.","journal-title":"Lancet Haematol"},{"key":"751_CR77","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140\u201351.","journal-title":"N Engl J Med"},{"issue":"17","key":"751_CR78","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","volume":"8","author":"AT Gerds","year":"2024","unstructured":"Gerds AT, Harrison C, Kiladjian JJ, et al. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024;8(17):4511\u201322.","journal-title":"Blood Adv"},{"issue":"Suppl. 1","key":"751_CR79","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1016\/S2152-2650(23)01234-X","volume":"23","author":"JJ Kiladjian","year":"2023","unstructured":"Kiladjian JJ, Harrison C, Mesa RA, et al. MPN-346 INDEPENDENCE: enrolling phase III trial to study the efficacy and safety of luspatercept versus placebo in patients with myelofibrosis on JAK2 Inhibitor (JAK2i) therapy requiring red blood cell transfusions (RBCTs). Clin Lymphoma Myeloma Leuk. 2023;23(Suppl. 1):S390.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl. 1","key":"751_CR80","first-page":"3191","volume":"144","author":"P Bose","year":"2024","unstructured":"Bose P, Gerds AT, Gupta V, et al. ODYSSEY: a phase 2 open-label study of momelotinib in combination with luspatercept in patients with transfusion-dependent myelofibrosis. Blood. 2024;144(Suppl. 1):3191.","journal-title":"Blood"},{"issue":"8","key":"751_CR81","first-page":"2660","volume":"109","author":"P Bose","year":"2024","unstructured":"Bose P, Masarova L, Pemmaraju N, et al. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024;109(8):2660\u20134.","journal-title":"Haematologica"},{"key":"751_CR82","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","volume":"384","author":"M Humbert","year":"2021","unstructured":"Humbert M, McLaughlin V, Simon JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384:1204\u201315.","journal-title":"N Engl J Med"},{"key":"751_CR83","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478\u201390.","journal-title":"N Engl J Med"},{"issue":"S3","key":"751_CR84","doi-asserted-by":"publisher","first-page":"e10730ab","DOI":"10.1097\/01.HS9.0000970872.10730.ab","volume":"7","author":"B Moses","year":"2023","unstructured":"Moses B, Wheeler A, Dills M, et al. P992: a modified activin receptor type II ligand trap RKER-050 restored erythropoiesis in a mouse model of myelofibrosis. Hemasphere. 2023;7(S3):e10730ab.","journal-title":"Hemasphere"},{"issue":"Suppl.","key":"751_CR85","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1097\/01.HS9.0000848500.38878.7f","volume":"6","author":"B Moses","year":"2022","unstructured":"Moses B, LaMora J, Nathan R, et al. P1410: RKER-050, a novel inhibitor of TGF-b superfamily signaling, induced platelet production in healthy mouse megakaryocytes. Hemasphere. 2022;6(Suppl.):1294\u20135.","journal-title":"Hemasphere"},{"issue":"Suppl. 1","key":"751_CR86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2020-140364","volume":"136","author":"M Feigenson","year":"2020","unstructured":"Feigenson M, Nathan R, Materna C, et al. KER-050, a novel inhibitor of TGF-b superfamily signaling, induces red blood cell production by promoting multiple stages of erythroid differentiation. Blood. 2020;136(Suppl. 1):34.","journal-title":"Blood"},{"issue":"Supplement 1","key":"751_CR87","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2021-152729","volume":"138","author":"R Nathan","year":"2021","unstructured":"Nathan R, Feigenson M, Lamora J, et al. RKER-050 rescued ruxolitinib (rux)-associated reductions in red blood cell volume. Blood. 2021;138(Suppl. 1):934.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"751_CR88","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood-2024-201729","volume":"144","author":"C Harrison","year":"2024","unstructured":"Harrison C, Chee LCY, Devos T, et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing phase 2 RESTORE trial. Blood. 2024;144(Suppl. 1):997.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"751_CR89","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1182\/blood-2023-181055","volume":"142","author":"MC Stubbs","year":"2023","unstructured":"Stubbs MC, Pusey M, Wen X, et al. ALK2 and JAK2 inhibition for improved treatment of anemia in myelofibrosis patients: preclinical profile of an ALK2 inhibitor zilurgisertib in combination with ruxolitinib. Blood. 2023;142(Suppl. 1):1789.","journal-title":"Blood"},{"issue":"Suppl.","key":"751_CR90","first-page":"P1060","volume":"8","author":"P Bose","year":"2024","unstructured":"Bose P, Oh S, Kiladjian JJ, et al. The activin receptor like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: phase 1\/2 study results. Hemasphere. 2024;8(Suppl.):P1060.","journal-title":"Hemasphere"},{"issue":"8","key":"751_CR91","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1172\/JCI25049","volume":"115","author":"FW Huang","year":"2005","unstructured":"Huang FW, Pinkus JL, Pinkus GS, et al. A mouse model of juvenile hemochromatosis. J Clin Invest. 2005;115(8):2187\u201391.","journal-title":"J Clin Invest"},{"issue":"Suppl. 1","key":"751_CR92","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood-2024-207686","volume":"144","author":"J Xu","year":"2024","unstructured":"Xu J, MacDonald B, Quisel J, Wu M. Anti-hemojuvelin monoclonal antibody alleviated anemia induced by ruxolitinib treatment in mice. Blood. 2024;144(Suppl. 1):1752.","journal-title":"Blood"},{"issue":"8","key":"751_CR93","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/jcph.2432","volume":"64","author":"N Novikov","year":"2024","unstructured":"Novikov N, Buch A, Yang H, et al. First-in-human phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of DISC-0974, an anti-hemojuvelin antibody, in healthy participants. J Clin Pharmacol. 2024;64(8):953\u201362.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 1","key":"751_CR94","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood-2024-203719","volume":"144","author":"N Gangat","year":"2024","unstructured":"Gangat N, Foran JM, Halpern AB, et al. A phase 1b study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia. Blood. 2024;144(Suppl. 1):657.","journal-title":"Blood"},{"issue":"32","key":"751_CR95","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.1200\/JCO.23.00833","volume":"41","author":"GA Palumbo","year":"2023","unstructured":"Palumbo GA, Duminuco A. Myelofibrosis: in search of BETter targeted therapies. J Clin Oncol. 2023;41(32):5044\u20138.","journal-title":"J Clin Oncol"},{"issue":"27","key":"751_CR96","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2217\/fon-2022-0484","volume":"18","author":"CN Harrison","year":"2022","unstructured":"Harrison CN, Gupta VK, Gerds AT, et al. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022;18(27):2987\u201397.","journal-title":"Future Oncol"},{"issue":"32","key":"751_CR97","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1200\/JCO.22.01972","volume":"41","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas J, Kremyanskaya M, Patriarcha A, et al. MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis. J Clin Oncol. 2023;41(32):4993\u20135004.","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"751_CR98","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1016\/S2152-2650(21)01835-8","volume":"21","author":"O Zavidij","year":"2021","unstructured":"Zavidij O, Keller P, Cui J, et al. MPN-343: the BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients in the phase 2 MANIFEST trial. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl. 1):S363\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"751_CR99","doi-asserted-by":"publisher","unstructured":"Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib plus ruxolitinib for JAK inhibitor-na\u00efve myelofibrosis: a randomized phase 3 trial. Nat Med. 2025.\u00a0https:\/\/doi.org\/10.1038\/s41591-025-03572-3.","DOI":"10.1038\/s41591-025-03572-3"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00751-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00751-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:12Z","timestamp":1769050992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00751-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00751-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"31 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D. received honoraria from BMS Celgene, Incyte, Janssen, AOP, Novartis and consulting fees from GSK, and AstraZeneca. P.H. received research funding from GSK, BMS, Novartis, Incyte, AOP, and Constellation and honoraria from GSK, Incyte, and Novartis. G.P. received consultancy and honoraria from AbbVie, AOP, AstraZeneca, BMS, Incyte, GSK, Morphosys, and Novartis. P.B. received research support from Incyte, BMS, CTI, a Sobi company, Morphosys (now Novartis), Kartos, Telios, Ionis, Disc, Geron, Ajax, Janssen, Sumitomo, Karyopharm, Blueprint, and Cogent; and honoraria\/consulting fees from Incyte, BMS, CTI, a Sobi company, GSK, AbbVie, Morphosys (now Novartis), Novartis, PharmaEssentia, Keros, Sumitomo, Karyopharm, Geron, Morphic, Jubilant, Ono, Raythera, Ionis, Disc, Cogent, and Blueprint. P.B. is the Editor-in-Chief of Curr. Hematologic Malig. Rep. H.T.C., E.T. and C.V. declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"7"}}